Chugai's satralizumab nabs accelerated review status in U.S. for eye nerve disorder

|About: Chugai Pharmaceutical ... (CHGCY)|By:, SA News Editor

The FDA designates Chugai Pharmaceutical's (OTCPK:CHGCY) Phase 3-stage satralizumab, an IL-6 receptor humanized recycling antibody, a Breakthrough Therapy for the treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders (NMO/NMOSD), autoimmune dysfunctions primarily affecting the optical nerves and spinal cord.

Breakthrough Therapy status provides for more intensive guidance from the FDA on development, the involvement of more senior agency personnel and a rolling review of the marketing application.

Chugai is majority owned by Roche (OTCQX:RHHBY).

Subscribe for full text news in your inbox